

ASX ANNOUNCEMENT

4 February 2026

CLEANSING NOTICE

Notification under s 708(5)(e) of the Corporations Act

HeraMED Limited (ASX:HMD) ('HeraMED' or the 'Company') advises that it has today issued 41,300,685 fully paid ordinary shares (**New Shares**) in accordance with the Company's ASX announcement on 27 January 2026 and Appendix 2A lodged today.

This notice is given by the Company under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

1. The New Shares were issued by the Company on 4 February 2026 without disclosure to investors under Part 6D.2 of the Corporations Act.
2. This notice is given under paragraph 5(e) of section 708A of the Corporations Act.
3. As at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act
4. As at the date of this notice, there is no information that is 'excluded information' within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Authorised by the HeraMED Board of Directors

HeraMED Limited**Managing Director & CEO**

Anoushka Gungadin

M: +61 431 131 649

E: anoushka@hera-med.com

CFO & Company Secretary

Cameron Jones

T: +61 400 086 399

E: cameron.jones@bio101.com

Chairman

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.